Pharma BD Deal Intelligence
In October 2002, InterMune Inc. and Inhale Therapeutic Systems Inc. entered a collaboration to develop a PEGylated formulation of Infergen (interferon alfacon-1), branded PEG-Infergen, for the treatment of chronic hepatitis C. Inhale contributed its PEGylation technology and exclusive manufacturing of the PEGylation reagent, while InterMune was responsible for preclinical and clinical development and North American commercialization. Inhale was eligible for milestone payments as the program advanced through the clinic plus royalties on product sales; specific financial terms were not disclosed.